| 寻亚诺,姬广凤,冯俊慧,张潇,蒋志浩.米那普仑联用低剂量奥氮平治疗重度抑郁症临床研究[J].济宁医学院学报,2021,44(3):197-200 |
| 米那普仑联用低剂量奥氮平治疗重度抑郁症临床研究 |
| Clinical efficacy and safety of milnacipran combined with low-dose olanzapine in the treatment of severe depression |
| 投稿时间：2021-03-05 |
| DOI：10.3969/j.issn.1000-9760.2021.03.011 |
| 中文关键词: 重度抑郁症;米那普仑;奥氮平 |
| 英文关键词: Major depression;Milnacipran;Olanzapine |
| 基金项目: |
| 作者 | 单位 | | 寻亚诺 | 济宁市精神病防治院, 济宁 272051 | | 姬广凤 | 济宁市精神病防治院, 济宁 272051 | | 冯俊慧 | 济宁市精神病防治院, 济宁 272051 | | 张潇 | 济宁市精神病防治院, 济宁 272051 | | 蒋志浩 | 济宁市精神病防治院, 济宁 272051 |
|
| 摘要点击次数: 1392 |
| 全文下载次数: 797 |
| 中文摘要: |
| 目的 评价米那普仑联用低剂量奥氮平治疗重度抑郁症的临床效果及不良反应。方法 选取2016年1月至2020年8月入本院治疗的80例重度抑郁症患者，随机分为观察组与对照组，每组40例，观察组联用米那普仑和低剂量奥氮平治疗8周，对照组单用米那普仑治疗8周。采用汉密尔顿抑郁量表（HAMD）和汉密尔顿焦虑量表（HAMA）量表评分评定临床疗效，副反应量表（TESS）评估安全性和不良反应。结果 治疗8周后，观察组总有效率92.5%，高于对照组82.5%（P<0.05）；治疗前两组HAMD评分和HAMA评分差异无统计学意义（P>0.05），治疗后第2、4、8周观察组HAMD评分低于对照组，治疗后第8周观察组HAMA评分低于对照组（P<0.05）；两组不良反应发生率差异无统计学意义（P>0.05）。结论 米那普仑合并低剂量奥氮平治疗重度抑郁症具有增效作用，疗效显著且安全性高。 |
| 英文摘要: |
| Objective To evaluate the clinical effect and adverse reactions of combined use of milnacipran and low-dose olanzapine in patients with depression.Methods From January 2016 to August 2020,80 hospitalized patients with severe depression in our hospital were selected and randomly divided into study group and control group,40 cases in each group.The study group were treated with milnacipran combined with low-dose olanzapine,and the control group was treated with milnacipran.Both groups were treated for 8 weeks.Hamilton Depression Scale (HAMD) and Hamilton Anxiety Scale (HAMA) were used to evaluate the clinical efficacy,and Tess was used to evaluate the safety and adverse reactions.Results The total effective rate of the study group was 92.5%,higher than 82.5% of the control group(P<0.05);there was no significant difference in HAMD score and HAMA score between the two groups before treatment(P>0.05);the HAMD score of the study group was lower than that of the control group at 2,4 and 8 weeks after treatment,and the HAMA score of the study group was lower than that of the control group at 8 weeks after treatment(P<0.05);the incidence of adverse reactions of the study group was lower than that of the control group;the difference between the adverse reaction occurence rates of the two groups was not statistically significant (P>0.05).Conclusion Milnacipran combined with low-dose olanzapine in the treatment of severe depression has synergistic effect,significant efficacy and high safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
|
|
|
